Compare Stocks: CRDL, ARDX, IVA, and GLAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.42 +1.2%	$4.27	$3.33 ▼ $8.40	$852.22M	0.7	3.80 million shs	6.43 million shs
CRDL Cardiol Therapeutics	$1.88 +0.8%	$1.66	$0.88 ▼ $2.34	$217.83M	0.79	1.50 million shs	972,938 shs
GLAS Glass House Brands	$7.89 -1.3%	$9.55	$5.15 ▼ $13.93	$747.59M	N/A	601,108 shs	676,183 shs
IVA Inventiva	$3.78 +0.8%	$4.52	$3.35 ▼ $7.98	$785.13M	0.71	1.18 million shs	1.05 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+1.18%	-4.47%	-15.14%	-43.47%	-44.75%
CRDL Cardiol Therapeutics	+0.81%	-6.02%	-4.34%	+76.89%	+73.61%
GLAS Glass House Brands	-1.07%	-0.08%	-18.90%	+788,499,900.00%	+788,499,900.00%
IVA Inventiva	+0.80%	-5.97%	-20.59%	+5.88%	-28.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.42 +1.2%	$4.27	$3.33 ▼ $8.40	$852.22M	0.7	3.80 million shs	6.43 million shs
CRDL Cardiol Therapeutics	$1.88 +0.8%	$1.66	$0.88 ▼ $2.34	$217.83M	0.79	1.50 million shs	972,938 shs
GLAS Glass House Brands	$7.89 -1.3%	$9.55	$5.15 ▼ $13.93	$747.59M	N/A	601,108 shs	676,183 shs
IVA Inventiva	$3.78 +0.8%	$4.52	$3.35 ▼ $7.98	$785.13M	0.71	1.18 million shs	1.05 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+1.18%	-4.47%	-15.14%	-43.47%	-44.75%
CRDL Cardiol Therapeutics	+0.81%	-6.02%	-4.34%	+76.89%	+73.61%
GLAS Glass House Brands	-1.07%	-0.08%	-18.90%	+788,499,900.00%	+788,499,900.00%
IVA Inventiva	+0.80%	-5.97%	-20.59%	+5.88%	-28.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	306.43% Upside
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	433.33% Upside
GLAS Glass House Brands	2.00	Hold	$16.00	102.92% Upside
IVA Inventiva	3.09	Buy	$15.75	316.67% Upside

Current Analyst Ratings Breakdown

Latest CRDL, ARDX, IVA, and GLAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/11/2026	GLAS Glass House Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/20/2026	GLAS Glass House Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	GLAS Glass House Brands	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.09	N/A	N/A	$0.69 per share	4.96
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	$5.07M	154.86	N/A	N/A	($0.22) per share	-17.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	14.25	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
GLAS Glass House Brands	N/A	N/A	N/A	39.43	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)

Latest CRDL, ARDX, IVA, and GLAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q2 2026	IVA Inventiva	-$0.20	N/A	N/A	N/A	$6.35 million	N/A
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
CRDL Cardiol Therapeutics	N/A	5.55	5.55
GLAS Glass House Brands	N/A	N/A	N/A
IVA Inventiva	N/A	3.16	3.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CRDL Cardiol Therapeutics	12.49%
GLAS Glass House Brands	N/A
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
CRDL Cardiol Therapeutics	5.25%
GLAS Glass House Brands	N/A
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
CRDL Cardiol Therapeutics	18	116.18 million	110.08 million	Not Optionable
GLAS Glass House Brands	357	93.80 million	N/A	N/A
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable

CRDL, ARDX, IVA, and GLAS Headlines

Recent News About These Companies

Inventiva (IVA) Projected to Post Quarterly Earnings on Friday

September 18 at 1:10 AM | americanbankingnews.com

Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Should You Buy?

September 16 at 3:59 PM | marketbeat.com

Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)

September 16 at 8:52 AM | theglobeandmail.com

Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 2:00 AM | seekingalpha.com

Inventiva To Present Lanifibranor Data Ahead Of Q4 NATiV3 Readout

September 10, 2026 | rttnews.com

Inventiva to Present Multiple Abstracts at Paris MASH 2026

September 8, 2026 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Buy" from Brokerages

September 6, 2026 | marketbeat.com

Inventiva (NASDAQ:IVA) Shares Gap Down - Here's Why

September 4, 2026 | marketbeat.com

Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4

September 3, 2026 | rttnews.com

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

September 2, 2026 | markets.businessinsider.com

Inventiva (NASDAQ:IVA) Shares Gap Up - What's Next?

September 2, 2026 | marketbeat.com

Inventiva names Chris Benecchi as COO ahead of pivotal lanifibranor readout

September 2, 2026 | thepharmaletter.comT

Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout

August 31, 2026 | rttnews.com

Chris Benecchi Named Inventiva’s New Chief Operating Officer

August 31, 2026 | finance.yahoo.com

INVENTIVA: Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finanznachrichten.de

Inventiva names Chris Benecchi as COO

August 31, 2026 | msn.com

Inventiva Appoints Chris Benecchi as Chief Operating Officer

August 31, 2026 | finance.yahoo.com

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

August 5, 2026 | seekingalpha.com

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

July 30, 2026 | globenewswire.com

Inventiva annonce ses résultats financiers préliminaires pour le premier semestre 2026¹

July 30, 2026 | lesoleil.comL

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

July 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRDL, ARDX, IVA, and GLAS Company Descriptions

Ardelyx NASDAQ:ARDX

$3.42 +0.04 (+1.18%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.43 +0.01 (+0.18%)

As of 09/18/2026 07:59 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$1.88 +0.02 (+0.81%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.93 +0.05 (+2.72%)

As of 09/18/2026 07:30 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Glass House Brands NYSE:GLAS

$7.88 -0.11 (-1.31%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$8.02 +0.13 (+1.65%)

As of 09/18/2026 07:41 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Inventiva NASDAQ:IVA

$3.78 +0.03 (+0.80%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.76 -0.01 (-0.40%)

As of 09/18/2026 06:58 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, ARDX, IVA, and GLAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, ARDX, IVA, and GLAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, ARDX, IVA, and GLAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRDL, ARDX, IVA, and GLAS Company Descriptions

Ardelyx NASDAQ:ARDX

Cardiol Therapeutics NASDAQ:CRDL

Glass House Brands NYSE:GLAS

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, ARDX, IVA, and GLAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, ARDX, IVA, and GLAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, ARDX, IVA, and GLAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRDL, ARDX, IVA, and GLAS Company Descriptions

Ardelyx NASDAQ:ARDX

Cardiol Therapeutics NASDAQ:CRDL

Glass House Brands NYSE:GLAS

Inventiva NASDAQ:IVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools